Other languages Cognition Therapeutics, Inc.

Equities

CGTX

US19243B1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
1.98 ^USD	+1.54%		+2.59%	+7.03%

Apr. 29	Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	CI
Apr. 12	Transcript : Cognition Therapeutics, Inc. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	Apr. 29
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
Cognition Therapeutics Prices $11.5 Million Stock Offering	Mar. 12
Cognition Therapeutics Starts Public Offering; Shares Decline	Mar. 11
Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	Mar. 11
Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer?s Disease Studies	Mar. 06
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-To-Mod Moderate Alzheimer's Disease	Nov. 07
Cognition Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director	23-10-27
Cognition Therapeutics, Inc. and Collaborators At Yale and ACTC Announce Oral Late-Breaking Presentation on the Start Study in Early Alzheimer?s Disease At CTAD	23-10-27
Cognition Therapeutics, Inc. Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease At CTAD	23-10-24
Top Premarket Decliners	23-10-06
Top Premarket Decliners	23-08-30
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Cognition Therapeutics, Inc. and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 Start Study in Early Alzheimer's Disease	23-07-05
Cognition Therapeutics Says Phase 2 Study of CT1812 Showed 'Positive Effects' in Alzheimer's Disease Patients	23-06-28
Top Premarket Gainers	23-06-28
Cognition Therapeutics, Inc. Announces Positive Topline Results for CT1812 Phase 2 Sequel Study for Mild-To-Moderate Alzheimerâ€™s Disease	23-06-28
Cognition Therapeutics, Inc. Publishes Clinical Evidence that CT1812 Displaces Aß Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease	23-05-18
Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cognition Therapeutics, Inc.

Equities

CGTX

US19243B1026

Other languages

Filters